Lozach Olivier

List of Publications by Citations

77 papers	3,388 citations	35 h-index	56 g-index
78 ext. papers	3,689 ext. citations	4.9 avg, IF	4.36 L-index

#	Paper	IF	Citations
77	Roscovitine targets, protein kinases and pyridoxal kinase. *Journal of Biological Chemistry*, **2005**, 280, 31208-19	3.4	278
76	Synthesis, anti-inflammatory, analgesic and kinase (CDK-1, CDK-5 and GSK-3) inhibition activity evaluation of benzimidazole/benzoxazole derivatives and some Schiff's bases. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 3758-65	3.4	213
75	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex. *Journal of Medicinal Chemistry*, **2008**, 51, 737-51	8.3	119
74	Synthesis and target identification of hymenialdisine analogs. *Chemistry and Biology*, **2004**, 11, 247-59		115
73	Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing. *Journal of Medicinal Chemistry*, **2011**, 54, 4172-86	8.3	107
72	Anticancer alkaloid lamellarins inhibit protein kinases. *Marine Drugs*, **2008**, 6, 514-27	6	104
71	Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase -3 alter circadian period. *Journal of Medicinal Chemistry*, **2008**, 51, 6421-31	8.3	98
70	Structure-based design and synthesis of 2-benzylidene-benzofuran-3-ones as flavopiridol mimics. *Journal of Medicinal Chemistry*, **2002**, 45, 1741-7	8.3	87
69	Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents. *European Journal of Medicinal Chemistry*, **2006**, 41, 296-305	6.8	85
68	Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases. *Cancer Research*, **2007**, 67, 8325-34	10.1	84
67	Synthesis and biological evaluation of novel phenylcarbazoles as potential anticancer agents. *Journal of Medicinal Chemistry*, **2006**, 49, 789-99	8.3	84
66	Synthesis, protein kinase inhibitory potencies, and in vitro antiproliferative activities of meridianin derivatives. *Journal of Medicinal Chemistry*, **2011**, 54, 4474-89	8.3	82
65	Synthesis of acridinyl-thiazolino derivatives and their evaluation for anti-inflammatory, analgesic and kinase inhibition activities. *Bioorganic and Medicinal Chemistry*, **2005**, 13, 4291-9	3.4	81
64	Synthesis of novel 5-substituted indirubins as protein kinases inhibitors. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 6434-43	3.4	78
63	9-cyano-1-azapaullone (cazpaullone), a glycogen synthase kinase-3 (GSK-3) inhibitor activating pancreatic beta cell protection and replication. *Journal of Medicinal Chemistry*, **2008**, 51, 2196-207	8.3	76
62	10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A. *Journal of Medicinal Chemistry*, **2015**, 58, 3131-43	8.3	70
61	Synthesis of chromeno[3,4-b]indoles as Lamellarin D analogues: a novel DYRK1A inhibitor class. *European Journal of Medicinal Chemistry*, **2012**, 49, 379-96	6.8	69

60	Synthesis and biological evaluation of 3,6-diamino-1H-pyrazolo[3,4-b]pyridine derivatives as protein kinase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 4566-9	2.9	67
59	3'-Substituted 7-halogenoindirubins, a new class of cell death inducing agents. *Journal of Medicinal Chemistry*, **2006**, 49, 4638-49	8.3	64
58	Antimalarial potential of xestoquinone, a protein kinase inhibitor isolated from a Vanuatu marine sponge Xestospongia sp. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 4477-82	3.4	61
57	New derivatives of pyrrolo[3,4-d]pyridazinone and their anticancer effects. *Il Farmaco*, **2004**, 59, 457-62		58
56	Novel Inverse Binding Mode of Indirubin Derivatives Yields Improved Selectivity for DYRK Kinases. *ACS Medicinal Chemistry Letters*, **2013**, 4, 22-26	4.3	57
55	Pyrazolo[3,4-c]pyridazines as novel and selective inhibitors of cyclin-dependent kinases. *Journal of Medicinal Chemistry*, **2005**, 48, 6843-54	8.3	57
54	Synthesis of 3,5-bis(2-indolyl)pyridine and 3-[(2-indolyl)-5-phenyl]pyridine derivatives as CDK inhibitors and cytotoxic agents. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 4932-53	3.4	51
53	Thiazolo[5,4-f]quinazolin-9-ones, inhibitors of glycogen synthase kinase-3. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 3419-23	2.9	51
52	Synthesis and biological evaluation of 2,3-diarylimidazo[1,2-a]pyridines as antileishmanial agents. *European Journal of Medicinal Chemistry*, **2012**, 58, 543-56	6.8	50
51	Novel 9-oxo-thiazolo[5,4-f]quinazoline-2-carbonitrile derivatives as dual cyclin-dependent kinase 1 (CDK1)/glycogen synthase kinase-3 (GSK-3) inhibitors: synthesis, biological evaluation and molecular modeling studies. *European Journal of Medicinal Chemistry*, **2008**, 43, 1469-77	6.8	50
50	Synthesis and kinase inhibitory activity of novel substituted indigoids. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 6257-63	3.4	49
49	Novel tetrahydropyrido[1,2-a]isoindolone derivatives (valmerins): potent cyclin-dependent kinase/glycogen synthase kinase 3 inhibitors with antiproliferative activities and antitumor effects in human tumor xenografts. *Journal of Medicinal Chemistry*, **2012**, 55, 9589-606	8.3	42
48	Novel CDK inhibition profiles of structurally varied 1-aza-9-oxafluorenes. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 823-5	2.9	41
47	Synthesis and biological evaluation of N-arylbenzo[b]thieno[3,2-d]pyrimidin-4-amines and their pyrido and pyrazino analogues as Ser/Thr kinase inhibitors. *European Journal of Medicinal Chemistry*, **2012**, 58, 171-83	6.8	40
46	Acridone alkaloids from Glycosmis chlorosperma as DYRK1A inhibitors. *Journal of Natural Products*, **2014**, 77, 1117-22	4.9	39
45	Synthesis, resolution, and biological evaluation of atropisomeric (aR)- and (aS)-16-methyllamellarins N: unique effects of the axial chirality on the selectivity of protein kinases inhibition. *Journal of Medicinal Chemistry*, **2013**, 56, 7289-301	8.3	39
44	Synthesis and biological evaluation of new 3-(6-hydroxyindol-2-yl)-5-(Phenyl) pyridine or pyrazine V-Shaped molecules as kinase inhibitors and cytotoxic agents. *European Journal of Medicinal Chemistry*, **2011**, 46, 5416-34	6.8	39
43	Biosynthesis of new indigoid inhibitors of protein kinases using recombinant cytochrome P450 2A6. *Chemistry and Biodiversity*, **2005**, 2, 51-65	2.5	36

42	Butyrolactone I derivatives from Aspergillus terreus carrying an unusual sulfate moiety. *Journal of Natural Products*, **2008**, 71, 689-92	4.9	35
41	Synthesis and optimization of an original V-shaped collection of 4-7-disubstituted pyrido[3,2-d]pyrimidines as CDK5 and DYRK1A inhibitors. *European Journal of Medicinal Chemistry*, **2014**, 80, 352-63	6.8	33
40	Synthesis, biological evaluation, and molecular modeling of natural and unnatural flavonoidal alkaloids, inhibitors of kinases. *Journal of Medicinal Chemistry*, **2012**, 55, 2811-9	8.3	29
39	Synthesis and preliminary biological evaluation of new derivatives of the marine alkaloid leucettamine B as kinase inhibitors. *European Journal of Medicinal Chemistry*, **2010**, 45, 805-10	6.8	29
38	Potent inhibitors of CDK5 derived from roscovitine: synthesis, biological evaluation and molecular modelling. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 125-31	2.9	28
37	Evaluation of the first cytostatically active 1-aza-9-oxafluorenes as novel selective CDK1 inhibitors with P-glycoprotein modulating properties. *Journal of Medicinal Chemistry*, **2003**, 46, 876-9	8.3	27
36	Synthesis and evaluation of the antiproliferative activity of novel thiazoloquinazolinone kinases inhibitors. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2005**, 20, 557-68	5.6	27
35	Access to Paullone Analogues by Intramolecular Heck Reaction. *Helvetica Chimica Acta*, **2007**, 90, 753-763		26
34	First BRET-based screening assay performed in budding yeast leads to the discovery of CDK5/p25 interaction inhibitors. *Biotechnology Journal*, **2011**, 6, 860-70	5.6	25
33	Antiinflammatory, analgesic and kinase inhibition activities of some acridine derivatives. *Open Chemistry*, **2004**, 2, 1-15	1.6	25
32	Synthesis, biological evaluation and molecular modeling studies of imidazo[1,2-a]pyridines derivatives as protein kinase inhibitors. *European Journal of Medicinal Chemistry*, **2016**, 123, 105-114	6.8	24
31	Concise synthesis and CDK/GSK inhibitory activity of the missing 9-azapaullones. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 4940-4	2.9	22
30	Synthesis and biological evaluation of new 5-benzylated 4-oxo-3,4-dihydro-5H-pyridazino[4,5-b]indoles as PI3K inhibitors. *European Journal of Medicinal Chemistry*, **2012**, 57, 225-33	6.8	21
29	Polyprenyl-hydroquinones and -furans from three marine sponges inhibit the cell cycle regulating phosphatase CDC25A. *Natural Product Research*, **2004**, 18, 1-9	2.3	21
28	Advances in tetrahydropyrido[1,2-a]isoindolone (valmerins) series: Potent glycogen synthase kinase 3 and cyclin dependent kinase 5 inhibitors. *European Journal of Medicinal Chemistry*, **2015**, 101, 274-87	6.8	20
27	Synthesis and biological evaluation of analogs of the marine alkaloids granulatimide and isogranulatimide. *European Journal of Medicinal Chemistry*, **2012**, 54, 626-36	6.8	20
26	Natural aristolactams and aporphine alkaloids as inhibitors of CDK1/cyclin B and DYRK1A. *Molecules*, **2013**, 18, 3018-27	4.8	17
25	Synthesis and biological evaluation of new penta- and heptacyclic indolo- and quinolinocarbazole ring systems obtained via Pd(0) catalysed reductive N-heteroannulation. *Organic and Biomolecular Chemistry*, **2010**, 8, 4625-36	3.9	16

24	A Pd(0) based cross-coupling approach to the synthesis of 2-amidopurines and their evaluation as CDK inhibitors. *Bioorganic and Medicinal Chemistry*, **2007**, 15, 130-41	3.4	16
23	Rebeccamycin derivatives as dual DNA-damaging agents and potent checkpoint kinase 1 inhibitors. *Molecular Pharmacology*, **2008**, 74, 1620-9	4.3	15
22	Synthesis of new pyridazino[4,5-b]indol-4-ones and pyridazin-3(2H)-one analogs as DYRK1A inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 5037-40	2.9	14
21	Phenanthrene derivatives from Appendicula reflexa as new CDK1/cyclin B inhibitors. *Phytochemistry Letters*, **2012**, 5, 814-818	1.9	14
20	Synthesis and Biological Evaluation of Bolaamphiphilic Sophorolipids. *ACS Sustainable Chemistry and Engineering*, **2018**, 6, 8992-9005	8.3	14
19	Several human cyclin-dependent kinase inhibitors, structurally related to roscovitine, are new anti-malarial agents. *Molecules*, **2014**, 19, 15237-57	4.8	13
18	Indirubins deplete striatal monoamines in the Intact and MPTP-treated mouse brain and block kainate-induced striatal astrogliosis. *Neurotoxicology and Teratology*, **2010**, 32, 212-9	3.9	13
17	Lipophosphoramidate-based bipolar amphiphiles: their syntheses and transfection properties. *Organic and Biomolecular Chemistry*, **2016**, 14, 2846-53	3.9	12
16	Catalyst-free synthesis of quinazolin-4-ones from (hetero)aryl-guanidines: application to the synthesis of pyrazolo[4,3-f]quinazolin-9-ones, a new family of DYRK1A inhibitors. *Molecular Diversity*, **2012**, 16, 659-67	3.1	12
15	Synthesis and biological evaluation of tetrahydro[1,4]diazepino[1,2-a]indol-1-ones as cyclin-dependent kinase inhibitors. *European Journal of Medicinal Chemistry*, **2014**, 83, 617-29	6.8	11
14	An Efficient Method for the Preparation of New Analogs of Leucettamine B under Solvent-Free Microwave Irradiation. *Heterocycles*, **2009**, 78, 1191	0.8	11
13	Synthesis, biological evaluation and molecular modelling studies of 4-anilinoquinazoline derivatives as protein kinase inhibitors. *Bioorganic and Medicinal Chemistry*, **2014**, 22, 1909-15	3.4	10
12	Suzuki-type Pd(0) coupling reactions in the synthesis of 2-arylpurines as Cdk inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 3144-6	2.9	10
11	Synthesis and evaluation of new potent inhibitors of CK1 and CDK5, two kinases involved in Alzheimer's disease. *Medicinal Chemistry Research*, **2013**, 22, 3247-3258	2.2	7
10	Further investigation of Paprotrain: Towards the conception of selective and multi-targeted CNS kinase inhibitors. *European Journal of Medicinal Chemistry*, **2016**, 124, 920-934	6.8	7
9	Substitution of unsaturated lipid chains by thioether-containing lipid chains in cationic amphiphiles: physicochemical consequences and application for gene delivery. *Organic and Biomolecular Chemistry*, **2019**, 17, 3609-3616	3.9	6
8	Combined Virtual and Experimental Screening for CK1 Inhibitors Identifies a Modulator of p53 and Reveals Important Aspects of in Silico Screening Performance. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	6
7	Azine and Diazine Functionalization Using 2,2,6,6-Tetramethylpiperidino-Based Lithium–Metal Combinations: Application to the Synthesis of 5,9-Disubstituted Pyrido[3?,2?:4,5]pyrrolo[1,2-c]pyrimidines. *Synlett*, **2015**, 26, 2811-2816	2.2	5

6	A practical approach to new (5Z) 2-alkylthio-5-arylmethylene-1-methyl-1,5-dihydro-4H-imidazol-4-one derivatives. *Molecules*, **2011**, 16, 7377-90	4.8	5
5	An expeditious, environment-friendly, and microwave-assisted synthesis of 5-isatinylidenerhodanine derivatives. *Chemical Papers*, **2011**, 65,	1.9	5
4	Identification of potential cellular targets of aloisine A by affinity chromatography. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 5572-82	3.4	5
3	Palladium-Catalyzed Synthesis of Substituted Pyrido[2,3-d]pyridazines at Positions 5 and 8. *Synthesis*, **2012**, 44, 3216-3224	2.9	4
2	A facile consensus ranking approach enhances virtual screening robustness and identifies a cell-active DYRK1 inhibitor. *Future Medicinal Chemistry*, **2018**, 10, 2411-2430	4.1	4
1	Synthesis of 6-Pyridylaminopurines. *Heterocycles*, **2008**, 75, 1735	0.8	3